CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹82 Cr | ₹184 Cr | ₹622 Cr | ₹1,660 Cr | ₹2,972 Cr |
What is the latest Total Non-Current Liabilities ratio of CIPLA ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹82 Cr |
Mar2023 | ₹184 Cr |
Mar2022 | ₹622 Cr |
Mar2021 | ₹1,660 Cr |
Mar2020 | ₹2,972 Cr |
How is Total Non-Current Liabilities of CIPLA Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹82 Cr | -55.36 | |
Mar2023 | ₹184 Cr | -70.48 | |
Mar2022 | ₹622 Cr | -62.55 | |
Mar2021 | ₹1,660 Cr | -44.15 | |
Mar2020 | ₹2,972 Cr | - |
Compare Total Non-Current Liabilities of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹121,324.6 Cr | -0.1% | 0.5% | 1.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹404,768.0 Cr | 0.4% | -1.2% | 12.2% | Stock Analytics | |
DIVIS LABORATORIES | ₹178,468.0 Cr | 2.6% | 8.4% | 48.5% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹113,757.0 Cr | 3.2% | 11.8% | 11.4% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹110,345.0 Cr | 3.4% | 0.5% | 12.8% | Stock Analytics | |
MANKIND PHARMA | ₹98,512.2 Cr | 1.4% | -6.4% | 11.8% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | -0.1% |
0.5% |
1.7% |
SENSEX | 0.3% |
0.7% |
8.8% |
You may also like the below Video Courses